Product
Sandostatin
2 clinical trials
2 indications
Indication
AcromegalyClinical trial
A Single-dose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Octreotide Injection in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-06-28
Clinical trial
A Phase 1b Study in Patients With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) to Characterize the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Debio 4126, a 12-week Prolonged-release Octreotide FormulationStatus: Active (not recruiting), Estimated PCD: 2024-11-01